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Introduction
The search for vaccines to protect against HIV/AID
has continued to elude the science world. However,
the use of highly active antiretroviral therapy
(HAART) has dramatically improved the prognosis
of  HIV-infected individuals1, 2.The beneficial effect
of reduced risk of early death from opportunistic
infections and other consequences of HIV infection,
is however, reduced because other possible causes
of death have replaced this beneficial effect3.
Myocardial infarction has become a matter of
particular concern. Two of  the main sources of
cardiovascular disease are believed to be vascular
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Back ground: Diet and genetic predisposition significantly affect lipid metabolism in the individual. This metabolic effect
is further challenged in patients infected with HIV and on HAART. The prolonged use of  HAART is associated with
lipodystrophy, dyslipidemia, and insulin resistance.
Objective: To determine the prevalence of  lipid dysregulation and dysglycaemia in HIV infected patients on HAART in the
Kumasi metropolis.
Methods: This cross sectional study was conducted between October 2009 and June 2010, and 305 HIV-infected patients
consisting of  164 patients on HAART for at least six months and 141 HAART-naive patients constituted HIV-positive
patients, not on HAART and whose CD4 were not below  320 cell/ml as the control. Data was analyzed using Graph Pad
Prism (version 5.0).  Unpaired t-test, linear and multivariate regression analyses, was used to predict glucose level from the
various parameters. Anthropometric parameters consisting of body weight, waist and hip circumferences, height, bicep and
triceps skin fold were measured with a pair of calipers. Lipid profile and fasting blood glucose were determined by enzymatic
methods. CD4 counts and hemoglobin were determined.
Results: Fasting plasma, glucose (3.81±0.08mmol/l, 4.48±0.17mmol/l), total cholesterol (3.05± 0.0 8mmol/l,
4.54±0.08mmol/l) LDL (2.24±0.07mmol/l, 2.87±0.07mmol/l) and HDL (0.85±0.04mmol/l, 0.97±0.03mmol/l) between
the control and case respectively were significantly raised (P< 0.001), though within the physiological range. The significantly
increased hip and waist circumferences, waist-to-hip ratio (0.85±0.22, 0.88±0.01) of the control and case correlated with
lipodystrophy.
Conclusion: HAART was associated with lipodystrohy and, the risk of developing type II diabetes among the HAART
experienced group was 5 times higher than the HAART naive group.
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inflammation and dyslipidemia. Unfortunately, the
use of these agents have given rise to metabolic and
morphological abnormalities termed lipodystrophy
syndrome and cardiovascular diseases4,5. There is
sufficient evidence that lipodystrophy is linked to
hypercholestrolaemia, hypertriglyceridaemia,
hyperinsulinaemia, peripheral insulin resistance and
even to overt diabetes6, 7.
Although there are differences between the  individual
drugs with respect to the  resulting metabolic
abnormalities, treatment with protease inhibitors (PI)
and to some extent nucleoside analogues such as
reverse transcriptase inhibitors (NRTIs) and non-
nucleoside reverse transcriptase inhibitors (NNRTIs)
are known to be associated with hyperlipidaemia,
h y p e r t r i g l y c e r e l d a e m i s , l y p o d y s t r o p h y,
hyperglycaemia and increased insulin resistance5,8. Low
levels of total and high-density lipoprotein
cholesterol (HDL-C) are also known to be associated
with chronic HIV infection9. Although this
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dyslipidaemia has been attributed to PI therapy,
dyslipidamia has also been observed in treatment-
naïve HIV-infected individuals suggesting that HIV
infection itself has a lipid metabolic derangement10,11.
Treatment with retonavir in healthy
volunteers resulted in hypertriglyceridaemia which is
not associated with impaired lipoprotein lipase
activity9 ,and treatment with indinavir may lead to
insulin resistance and lipid metabolic dysregulation12.
However, the exact mechanism by which the HIV
infection or HAART  induces dyslipidaemiais still
being researched into. Carpentier, et al.13 showed that
insulin-mediated suppression of plasma free fatty
acid concentrations was impaired both prior to and
following introduction of  HAART, compared to
healthy, matched controls.VLDL-apoB and VLDL-
TG concentrations rose significantly from normal
levels after HAART. Compared to healthy control
subjects, VLDL fractional catabolic rate and clearance
in HIV-seropositive individuals was reduced
approximately by 40%, and this defect was not
corrected after HAART. The increase in VLDL after
HAART was associated with an increased VLDL-
apoB and VLDL-TG secretion towards the normal
while the impaired VLDL clearance remained
unchanged.
Susceptibility to the development of these
metabolic defects varies with the individual and could
be influenced by genetic difference14. The recently
observed association between the APOC3-related
rs10892151 polymorphism and serum triglyceride
levels led to the believe that genetic differences may
play a major role in human immunodeficiency virus
(HIV) antiretroviral therapy-induced dyslipidemia15.
Although similar result have been reported in Asia,
America and Europe very little work in Ghana has
been done to determine the effect of  HAART on
lipidystrophy in HIV patients and particularly in the
Ashanti region of Ghana, a population with a
difference in ethnicity and dietary (from Europe and
America) which may all have effect on fat and
carbohydrate metabolism.
Methods
The study was carried out at Kumasi South Hospital
with the permission ofthe National Aids Control
Programme. All procedures were approved by the
Committee on Human Research Publication and
Ethics of School of Medical Sciences, KNUST
(CHRPE/Student/113/09). A written informed
consent form was completed by all the participants
who were recruited into the study after the study
was explained in a language they understand. Pre-
tested questionnaires were used to record
information of  the participants. Information on
demography, life style, physical examination and
anthropometric measurements were taken.
Study design
A cross sectional comparative study of  305 HIV-
infected patients conducted between October 2009
and June 2010. Out of this number, 164 patients
were on highly active antiretroviral therapy for at
least six months and above (HAART- experienced)
and 141 HAART- naïve,  patients constituted HIV-
positive patients, not on HAART and whose CD4
was not below the critical value of 320 cell/ml).
The age range of the HAART experienced was 22
to 60 years, (mean ± S.E.M of  38.18±0.65 years)
and that of the HAART naïve, between 20 to 64
years (mean ± S.E.M of  38.81±0.76 years). Of  the
164 HAART experienced participants, 122 (74.4%)
were females and 42 (25.6%) were males, (mean ±
S.E.M of  37.33±0.77 and 40.64±1.16 respectively).
The HAART-naïve group had 86 (61.0%) participants
being females and 55 (39.0%) males (mean ± S.E.M
of 36.59±1.01 and 42.27±1.01 respectively).
WHO recommended antiretroviral
medicines were used: Stavudine, lamivudine,
Efavirenz, Zidovudine and Nevirapine. All the
HAART experienced participants involved in the
study used a combination of these medicines,
grouped under NRTI consisting:Stavudine,
lamivudine and Zidovudine and NNRTI consisting
of Nevirapine and Efavirenz. The combination
consisted of a Stavudine based lamivudine with either
Nevirapine or Efavirenz and a Zidovudine based
lamivudine combined with either Nevirapine or
Efavirenz.
Participants with opportunistic infections, pregnant
women and patients with known type I and II
diabetes and (or) hypertension before HAART were
excluded.
Anthropometric measurement
Body weights were measured (to the nearest 0.5
kilogram), with the subject standing on a  weighing
scale after it was adjusted to zero kg, and calibrated
using known weights. Heights were measured (to
the nearest 1.0 centimeter), with the subject standing
in an erect position against a vertical scale of portable
standiometer and an L-square placed on the head,
and the head positioned tolevel with the inferior
margin of the bony orbit. The waist measurements
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were taken from the middle point between the iliac
crest and the last rib, as recommended by the World
Health Organization. Hip circumference was
measured as the maximal circumference over the
buttocks. Hip and Waist circumferences were
measured twice to the nearest centimeter and the
mean were used for subsequent analysis. Skin fold
measurement was done with a pair of calipers (Body
care CV47 OD, UK) at four standard points:
subscapular (on the Back below shoulder blade),
suprailiac (Side of  waist), bicep and triceps skin folds.
All measurements were read in centimeters (cm) but
the height was converted to meters. BMIs were then
calculated as weight in kilograms divided by the height
in meter squared.
Sample preparation and Biochemical assay
Fasted blood samples (overnight fast between 8-12
hours) were drawn from the median cubital vein on
the anterior forearm into plain and fluoride oxalate
tubes, BD vacutainer®, (BD, Plymouth, PL6 7BP.
UK), to prevent glycolysis.
The clotted blood was centrifuged using centrifuge
(D-78532, Tuttlingen, Germany) at 2000 rpm for 5
minutes to separate out the serum. The serum was
used to estimate the lipid profile: Total cholesterol
(TC), High density lipoprotein cholesterol (HDL),
low density lipoprotein(LDL) and triglycerides
(TRG) were estimated by direct enzymatic assay with
Selectra Junior (Vital Scientific, N.V. Netherlands)
automated assay. Protocol for assay by the kit
manufacturer (ELITECH DIAGNOSTICS) was
strictly adhered to. Interassay coefficient of  variation
(2.3% and 2.1% for low and high total cholesterol
controls respectively comply with National
Cholesterol Education Programme
recommendation16.  The remaining serum which was
not immediately used was stored at -20oC.
Anticoagulated blood was gently mixed with blood
mixer (Sarstedt, D-5223, Numbrecht, West
Germany). Haemoglobin concentration was
estimated with Sysmex (KX-21N) and Cluster of
differentiation 4 (CD
4
) was done with Becton
Dickinson FACSCount® (BD Biosciences, San Jose,
CA 95131 USA). The fluoridated anticoagulated
blood was centrifuged (Zentrifugen, D-78532,
Tuttlingen, Germany) at 3000 rpm for 5 minutes to
separate the plasma from the deposit. The plasma
was used to estimate the fasting blood glucose(FBS)
by enzymatic method using the automated Selectra
Junior.
Normal value range of  measured parameters in
Kumasi Laboratory include (FBS 3.3 6.4 mmol/l
,TC;3.1-6.5 mmol/l, TRIG 0.3-1.7mmol/l, HDL
0.75-1.88 mmol/l, LDL. 3.88-4.91 mmol/l) 17were
used to determine the lower and higher parameters
levels.
Statistical analysis
Data were entered into Microsoft Office Excel
version 11.0 (Microsoft Corporation, USA), and
further analyzed using Graph Pad Prism (version 5.0).
The unpaired t-test was done for the mean ±SD
with the 95% confidence interval. Statistical
significance was set at p-valuesd < 0.05 for the various
parameters in the study. A linear regression and
multivariate regression analyses, was done
considering sex and the measures of fat distribution
to find predictors of glucose level from the various
parameters.
Results
Height, body weight, waist circumference, Waist-to-
Hip ratio, bicep skin fold, systolic and diastolic blood
pressure were all significantly higher (p<0.0001) in
the HIV-infected HAART experienced patients than
the control. There were no significant differences
between the subjects and the control for BMI,
subscapular skinfold. A similar trend was observed
for the female and male subjects in comparison to
the general population. Even though these parameters
were significantly higher in the subjects than the
controls all these parameters were within the
physiological control levels.
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Table 1: Anthropometric parameters of  the Study population




P-value Female cases  
(N=122) 
P-value Male cases  
(N=42) 
P-value 
Age(years) 38.81±0.76 38.18±0.65 0.5290 37.33±0.77 0.5616 40.64±1.16 0.2914 
Height(m) 1.52±0.01 1.60± 0.01 <0.0001 1.57±0.01 <0.0001 1.67±0.02 <0.0001 
BW(kg) 54.87±0.90 60.37±0.73 <0.0001 59.54±0.89 0.0002 62.79±1.14 0.0005 
BMI(Kg/m2) 23.98±0.44 24.07±0.33 0.8729 24.47±0.39 0.8842 22.90±0.67 0.5956 
WC(cm) 77.35±0.68 83.77±0.67 <0.0001 84.25±0.82 <0.0001 82.40±1.08 0.0050 
HC(cm) 91.16±0.62 95.21±0.70 <0.0001 96.02±0.85 <0.0001 92.86±1.10 0.2952 
WHR 0.85±0.00 0.88±0.01 <0.0001 0.88±0.01 0.0001 0.89±0.01 0.0005 
Biceps(mm) 4.18±0.22 5.78±0.24 <0.0001 6.25± 0.29 0.0002 4.40±0.27 0.0089 
Triceps(mm) 8.90±0.47 10.41±0.46 0.0232 12.02±0.54 0.0393 5.71±0.31 0.1114 
SC(mm) 11.79±0.45 12.92±0.48 0.0869 14.24±0.56 0.0399 9.10±0.60 0.1009 
SI(mm) 8.57±0.34 9.11± 0.37 0.2912 9.89±0.41 0.2935 6.86±0.77 0.4205 
SBP(mmHg) 103.62±1.26 116.34 ±1.35 <0.0001 115.49±1.58 <0.0001 118.81±2.55 <0.0001 
DBP(mmHg) 67.80±0.84 75.37±1.01 <0.0001 75.08±1.19 0.0001 76.19±1.93 <0.0001 
 BW: Body weight; BMI: Body mass index; WC: Waist circumference; HC: Hip circumference; WHR: Waist to
hip ratio; SC: Subscapular skin fold; SI: Suprailiac skin fold; SBP: Systolic blood pressure; DBP: Diastolic
blood pressure and S.E: Standard error of  the mean.











Hb(g/dl) 10.43±0.14 11.77±0.12 <0.0001 11.69±0.14 <0.0001 12.01±0.22 <0.0001
CD4(cells/ul) 233.35±16.69 358.71±17.29 <0.0001 370.85±20.89 0.0005 323.45±29.29 0.0003
FBS(mmol/l) 3.81±0.08 4.48±0.17 0.0005 4.59±0.21 0.0015 4.16±0.24 0.1904
TC(mmol/l) 3.65±0.08 4.54±0.08 <0.0001 4.69±0.09 <0.0001 4.09±0.15 0.0015
TRIG(mmol/l) 1.37±0.07 1.37±0.07 0.9967 1.38±0.08 0.8093 1.34±0.13 0.7174
HDL-C(mmol/l) 0.85±0.04 0.97±0.03 0.0122 1.01±0.04 0.1645 0.86±0.06 0.0962
LDL-C(mmol/l) 2.24±0.07 2.87±0.07 <0.0001 2.98±0.09 <0.0001 2.53±0.09 0.0086
Hb: Hemoglobin concentration; CD4: Cluster of differentiation 4; FBS: Fasting blood   glucose
TC: Total Cholesterol; TRG: Triglycerides; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density
lipoprotein cholesterol
CD4 count, FBS, Total cholesterol, HDL and LDL
were significantly (p<0.0001) elevated in HIV-infected
HAART  experienced patients. However, there was
no significant change in the triglycerides levels
between the control population and the subject
population. A similar trend was observed for the
female and male subjects in comparison to the general
population. Even though these parameters were
significantly higher in the subject than the controls all
these parameters were within the physiological
control levels except for the CD4 count.
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F M F M F M F M
Lipoatrophy
Face 17 1 5 6 3 3 2 2 39
Limbs 5 2 4 1 4 2 0 0 18
Lipohypertrophy
Neck 19 5 7 3 14 2 1 1 52
Breast 12 1 2 0 10 2 0 0 27
Abdomen 13 5 8 2 7 5 7 1 48
Buttocks 8 3 3 1 5 2 0 0 22
F: Female, M: Male
Table3.Shows fat distribution, in association with HAART used and gender across the study population
24% HAART experienced participants had facial fat
depletion. Of this figure, 18 were using d4T/3TC/
NVP combination therapy, 11, 6 and 4 were using
d4T/3TC/EFV, AZT/3TC/NVP and AZT/3TC/
EFV respectively. Participants on AZT/3TC/EFV
combination therapy had no changes in appearance
in terms of  fat depletion on the limbs as well as fat
accumulation in the breast and buttocks. 18, 10, 12,
8 had truncal obesity after using d4T/3TC/NVP,
d4T/3TC/EFV, AZT/3TC/NVP and AZT/3TC/
EFV combination therapy respectively.
When the result of fasting glucose was
compared to duration of antiretroviral therapy (table
4.), 4.3% HAART experienced participants
developed type II diabetes between 6-18 months
on the therapy. Also, 0.6% and 1.8% HAART
experienced participants developed type II diabetes
between19-31 and after 31 months on therapy
respectively. Of  the 4.3% HAART experienced
participants who developed IFG, 1.2% developed
IFG between 6-18 months. 2.4% developed IFG
between 19-31 months and 0.6% developed IFG
after 31 months on therapy (table 4).
Family history of hypertension and type II diabetes
are important risk factors of cardiovascular disease
and diabetes. In this study, participants with a family
history of type II diabetes had 7 times the chance
of developing type II diabetes among the HAART
experienced group: X2(P), 8.6(0.0034).
Further analysis of  the data suggest that
HAART  experienced subjects were 5 times more
likely to develop type 2 diabetes, and raised CD4
count, four times likely to develop
hypercholesterolemia and a significantly reduced
chances of raised HDL and LDL, and a non-
significanttriglyceride change (table 5).




Total Female Male Total Female Male Total Female Male
6-18 98 67 31 2 2 0 7 5 2
19-31 30 26 4 4 4 0 1 1 0
31+ 18 13 5 1 1 0 3 3 0
Total 146 106 40 7 7 0 11 9 2
IFG: impaired fasting glucose; Duration: Duration of HAART in months
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Table 5: Assessment of  biochemical parameters as risk factors of  development of  diabetes and
CVD
Parameters Control Case OR(95% CI) Chi2 P-Value
FBS(mmol/l) Low 83(58.9) 86(52.4) 0.9(0.6-1.5) 0.08 0.7780
*Normal 55(39.0) 61(37.2) 1
High 3(2.1) 17(10.4) 5.1(1.3-28.4) 7.33 0.0068
TC(mmol/l) Low 45(31.9) 15(9.2) 0.2(0.1-0.4) 23.68 0.0000
*Normal 95(76.4) 143(87.2) 1
High 1(0.7) 6(3.7) 4.0(0.5-185.2) 1.87 0.1710
TRIG(mmol/l) Low 0(0) 1(0.6) ------ 0.87 0.3502
*Normal 113(80.1) 129(78.7) 1
High 28(19.9) 34(20.7) 1.1(0.6-1.9) 0.05 0.8290
HDLC(mmol/l) Low 84(59.6) 71(43.3) 0.4(0.3-0.8) 10.44 0.0012
*Normal 48(34.0) 88(53.7) 1
High 9(6.4) 5(3.1) 0.3(0.1-1.1) 4.53 0.0333
LDLC(mmol/l) Low 138(97.9) 143(87.2) 0.1(0.0-0.6) 8.98 0.0027
*Normal 2(1.4) 15(9.2) 1
High 1(0.7) 6(3.7) 0.8(0.0-55.0) 0.03 0.8652
CD4(cells/ul) *Low 52(36.9) 18(11.0) 1
Normal 89(63.1) 146(89.0) 4.7(2.5-9.1) 28.77 0.0000
FBS: Fasting blood glucose; TC: Total cholesterol; TRIG: Triglycerides; HDLC: High density lipoprotein
cholesterol; LDLC: Low density lipoprotein cholesterol; CD
4
: Cluster of differentiation 4. OR; Odd Ratio
(crude), CI, Confidence Interval.
Table 5 presents the analysis for co morbidity for type II diabetes and CVD. Total cholesterol was higher in
the cases than the control and the difference was statistically significant (P=0.0068). Also, LDL in the cases
were nonsignificantly higher than in the controls (P=0.8652)
Table 6: Assessment of  family history as risk factor of  development of  diabetes and CVD
Parameters Control Case OR(95%CI) Chi2 P-
Value
FHDiabetes *No 139(98.6) 149(90.9) 1




*No 136(96.5) 146(89.0) 1
yes 5(3.6) 18(11.0) 3.4(1.2-11.8) 6.00 0.0143
FH: Family history, OR: Odd Ratio
Discussion
The use of HAART has significantly decreased
morbidity and mortality in HIV infected patients
leading to an increase in life expectancy. However,
the benefits of antiretroviral combination therapy
are associated with a wide spectrum of side effects
with some clinical manifestations18,19. Lipodystrophy,
hyperlipidaemias, insulin resistance, hyperglycaemia
and even overt diabetes has been reported in subjects
treated with protease inhibitors (PIs) and nucleoside-
reverse transcriptases inhibitors (NRTIs)20.
Aclassification of morphological and metabolic
abnormalities following HAART administration is
summarized in Table.1.Suprailiac skinfold and BMI
were not significantly changed between the subject
and control. BMI has been shown in several studies
not to give a good reflection of body fat distribution
but fat to muscle mass ratio (obesity)21. Indeed waist
circumference, hip circumference and hip-to-waist
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ratios which have been shown to be better reflectors
of body fat distribution, were significantly elevated
in the HIV-infected patients on HAART.
Dyslipidaemia in the HIV–infected, is characterized
by hypertriglyceridaemia, and low  HDL levels22. This
is mostly attributed HAART treatment.The
prolonged surge of pro inflammatory cytokines such
as TNF-alpha, IL-1, IL-6 IFN-alpha observed
following the chronic state of  HIV infection have
been shown to contribute to   lipid dysrgulation23.
Cytokines such as TNF-alpha, IL-1, IL-6 IFN-alpha
have also been reported to increase lipogenesis,
decrease clearance of circulating LDL and inhibit
hepatic lipase activity24, 25. This probably partly
account for the observed slightly increase in serum
LDL levels in this study.
Dyslipidaemia has also been observed in
HAART-naive HIV-infected patients, suggesting that
HIV-infection itself  has a metabolic deleterious
effect10,11. It is not however certain whether these
complications are exclusively due to the viral load
or associated with HAART recommended by the
WHO5,26. The changes in the lipid profile in this study
were similar in the male and female cases suggesting
that the fat distribution were not exclusively due to
gender effect27. In several studies in Ghana, women
have been shown to have higher waist circumference,
hip circumference and hip-to-waist ratios28 as
opposed to what is typically reported in the Western
World. It therefore implies that HAART is the main
cause of lipid redistribution in this study since these
anthropometric parameters were raised  in both male
and female alike. HIV-infected patients did not show
dyslipidaemia despite having been on HAART for
well over six months (table 2). Lipid changes were
all within the physiological range. However, Total
cholesterol, HDL and LDL were significantly
(p<0.0001) elevated in the HAART-experienced
patients while triglycerides were not significantly
changed. The elevated HDL contradictsthe effect
of NRTI treatment which has been shown to lower
HDL levels10,11,19.
Hence combination treatment with NNRTI
and NRTI drugs may therefore be more beneficial
than treatment with only one of the nucleosides,
because elevated HDL has a positive effect in lipid
metabolism as it increases reverse cholesterol
transport effect and therefore anti-atherogenic and
possibly partly accounting for the observed
physiological level of  the lipids. It is also possible
that this observation could be explained by genetic
influence and or the low diet fat in the Ghanaianas
compared to the fat rich western diet, or due to the
dietary restriction as part of treatment package.
Indeed, HIV-infected patients require aggressive
treatment including low-fat diets, avoidance of
simple sugars, and elimination of alcohol intake29.
The advert effect of high fat diet on health and fat
distribution has been extensively studied30,31.
Lipodystrophy characterized by peripheral loss of
fat tissue and abnormal fat distribution including the
enlargement of  dorsocervical fatpad, lipomatosis,
breast hypertrophy, and visceral abdominal fat
accumulation have recently been reported in HIV-1
patients receiving HAART6,32-3540. In this study the
combined use of NNRTI and NRTI resulted in 24%
of the subjects experiencing facial fat depletion.
However, participants on AZT/3TC/EFV
combination therapy had no changes in appearance
in terms of  fat depletion on the limbs as well as fat
accumulation in the breast and buttocks. About 29%
had truncal obesity after using the various
combinations of NRTI and NNRTI (table 3). The
association between visceral obesity and NRTI
therapy has been reported in several studies32, 43.
The development of diabetes and or insulin resistance
is not only due to hyperlipidaemia but also
lipodystrophy5,8. Indeed increased visceral fat has
been shown to be associated with the development
of type2 diabetes whilst peripheral and subcutaneous
fat levels, inversely correlates to the development of
type 2 diabetes. Haffner, et al. 36found that WHR
was a better single screening measure for NIDDM
than BMI and that upper body adiposity predicted
diabetes even in leanmen and women. Ohlson,et al.37
also found that WHR was positively and significantly
associated with NIDDM even after BMI was
considered among men.
Metabolic syndrome has been reported in
HIV patients on HAART38. Hyperglycemia, and
insulin resistancethe hallmark of metabolic syndrome
mostly associated with HIV  patients receiving
protease inhibitors, have been implicated in patients
on NRTIs alone39. The development of insulin
resistance and diabetes with HAART is time
dependent. In this study  4.3% HAART experienced
participants developed type II diabetes between 6-
18 months on therapy and 6.1% between19-31 and
after 31 months, whilst 1.2% of the 4.3% developed
IFG between 6-18 months. 3.0% developed IFG
between 19-31 months and after 31 months on
therapy (table 4). Several mechanisms have been
proposed to explain this phenomenon.  Among
these, the animal and human models of diabetes
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mellitus suggest that mitochondrial dysfunction is
significantly related to the development of insulin
resistance. Several studies have also shown that
Nucleoside reverse transcriptase inhibitors (NRTIs)
impair mitochondrial function in individuals infected
with human immunodeficiency virus (HIV)41 42
Even though the fasting blood glucose was
significantly higher in the subjects, the significance
of  the difference between the HAART-experienced
and HAART-naïve groups as well as among the
subgroups, was lost when the data was subjected to
further statistical analyses to determine if  this
significance could correlate to the development of
type 2 diabetesX2(P): 0.4(0.7904) X2(P): 3.1(0.2136).
However, the  risk of developing type II diabetes
among the HAART experienced group was 5 times
higher than the HAART naive group: X2(P),
7.3(0.0068) (table 5).
The distribution of fat also shows a tendency to the
development of hypertension. Even though the
systolic and diastolic blood pressures in both
HAART-naïve and HAART- experience subjects
were within the physiological range, the levels in the
HAART-experienced were significantly elevated
(table1).
Family history of hypertension and type II
diabetes are important risk factors for the
development of  these diseases. In the study, the
HAART experienced group,with a family history of
type II diabetes were 7 times more likely to develop
type II diabetes than the HAART -naive: data not
shown (table 6).
Conclusion
Waist circumference, hip circumference and waist-
to-hip ratio which are the key indices for assessing
body fat distribution were significantly raised in
HAART-experienced than HAART-naïve HIV-
infected patients in Kumasi, implying that HAART
could result to lipodystrophy. Even though the
quantitative values of triglycerides, high density
lipoprotein, low density lipoprotein and total
cholesterol were all within the physiological range,
total cholesterol, low density lipoproteins and high
density lipoproteins were significantly raised
(p<0.0001) in the HAART-experienced. The raised
HDL level as a result of  the combined use of  NRTI’s
and NNRTI’s in this study may therefore serve to
improve reverse cholesterol transport and therefore
bringing the lipoproteins to the physiological level
and their use would be much recommendable.Also,
though the fasting blood glucose levels were not
significantly different between the control and the
subjects, the tendency for the HAART patients to
develop dysglycaemia was 5 times higher than the
HAART-naive group.
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